SCHEMBL5337634

SCHEMBL5337634

COc1cccc2cc3c(O)cc(=O)oc3cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 1/20 0.53
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
POLB P06746 1/20 0.51
EIF4H Q15056 1/20 0.51
CYP2A6 P11509 2/20 0.50
CA12 O43570 6/20 0.48
CA1 P00915 6/20 0.48
CA9 Q16790 6/20 0.48
CA7 P43166 3/20 0.48
AKR1B1 P15121 2/20 0.48
MCL1 Q07820 2/20 0.48
CA13 Q8N1Q1 2/20 0.48
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
CYP1A2 P05177 1/20 0.47
GLA P06280 1/20 0.47
AMY1A P0DUB6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5337919 0.82 CA12 (0.54) CTDSP1KMT2AMEN1POLBCA12
SCHEMBL5340608 0.80 MAOB (0.50) KMT2AMEN1CA12CA1CA9
SCHEMBL5337318 0.79 MCL1 (0.54) KMT2AMEN1POLBCA12CA1
SCHEMBL27903498 0.77 ALDH1A1 (0.59) KMT2AMEN1POLBCA12CA1
SCHEMBL2762362 0.77 CA12 (0.65) CTDSP1KMT2AMEN1POLBCA12
SCHEMBL5342730 0.76 MAOA (0.56) CTDSP1KMT2AMEN1POLBEIF4H
SCHEMBL8955962 0.75 KDM4E (0.56) CTDSP1KMT2AMEN1CA1KDM4E
SCHEMBL20317243 0.75 NPC1 (0.71) KMT2AMEN1CYP2A6CA1KDM4E
SCHEMBL5348687 0.75 MAOA (0.56) CTDSP1KMT2AMEN1POLBEIF4H
SCHEMBL11845819 0.75 KDM4E (0.51) CTDSP1KMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208518-B2 Substituted furochromene compounds of antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2007-04-24 US disclosed
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action PLIVA-LSTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648901-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010006-A1 SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148890-A1 Substituted furochromene compounds of antiinflammatory action LTC4S, CYP11B2, CYP11B1 CTDSP1 1437/4885KMT2A 4671/4885MEN1 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.